Agios Pharmaceuticals, Inc.

AGIO

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Placebo Matching Mitapivat	Phase 3	Non-Transfusion-dependent Alpha-Thalassemia	-
Placebo	Phase 3	Pyruvate Kinase Deficiency	-
Mitapivat-matching placebo	Phase 3	Pediatric Pyruvate Kinase Deficiency	-
Mitapivat	Phase 3	Sickle Cell Disease	-
Tebapivat	Phase 2	Myelodysplastic Syndromes	-
Tebapivat Matched Placebo	Phase 2	Sickle Cell Disease	-
AG-348	Phase 2	Pyruvate Kinase Deficiency	-

Catalyst Timeline

3 upcoming, 0 past

Phase 2Next

March 2026~Tebapivat

Primary completion for Tebapivat trial (NCT05490446) in Myelodysplastic Syndromes

Phase 2

May 2026~Tebapivat

Primary completion for Tebapivat trial (NCT06924970) in Sickle Cell Disease

Phase 2

May 2026~Tebapivat Matched Placebo

Primary completion for Tebapivat Matched Placebo trial (NCT06924970) in Sickle Cell Disease

Regulatory Approvals

AGIO News